Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.

Acta Diabetologica
Shubing JiaJingyu Yang

Abstract

Although there are many different methods of treating type 2 diabetes (T2D), it is still difficult to draw coincident conclusions concerning the efficacy and safety of different classes of new drugs, and the recommendation level of them has still kept uncertain as second anti-diabetic agents. Therefore, the aim of this study was to summarize evidence on the efficacy and safety of DPP-4is, GLP-1RAs and SGLT-2is as monotherapy or add-on to metformin (Met) for treatment of T2D. We searched PubMed, Embase, Cochrane library and ClinicalTrials.gov for relevant articles in keeping with established methods using terms associated with anti-diabetic agents up to February, 2020, with no start date restriction. Weighted mean difference and risk ratios with 95% confidence intervals were calculated within traditional and network meta-analysis. Primary outcomes were the mean change in hemoglobin A1c (HbA1c), fasting plasma glucose (FPG) change and the frequency of hypoglycemic events from baseline after 12 weeks of treatment. In total, 64 eligible studies comprising 37,780 patients and 7 treatment strategies were included. The results of primary outcomes showed that GLP-1RAs were significantly more effective than DPP-4is or SGLT-2is in reduci...Continue Reading

References

Jan 1, 1986·Diabetologia·M NauckW Creutzfeldt
Oct 15, 2005·BMJ : British Medical Journal·Deborah M CaldwellJ P T Higgins
May 19, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·A SchweizerS Dejager
Jan 16, 2008·Current Medical Research and Opinion·Itamar RazMaria Alba
Jan 19, 2008·Diabetes, Obesity & Metabolism·R ScottUNKNOWN Sitagliptin Study 801 Group
Dec 31, 2008·Diabetes Care·James F ListFred T Fiedorek
Feb 18, 2009·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·M GoodmanJ Penman
Dec 19, 2009·American Journal of Hypertension·Ted OkersonRobert Brodows
Jan 15, 2010·Diabetes, Obesity & Metabolism·P AschnerUNKNOWN Sitagliptin Study 049 Group
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Dec 24, 2011·Diabetes, Obesity & Metabolism·V FonsecaB Hirshberg
Mar 1, 2012·Diabetes, Obesity & Metabolism·C PanUNKNOWN Institution Investigators
Mar 31, 2012·International Journal of Epidemiology·Rebecca M TurnerJulian Pt Higgins
Nov 10, 2012·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Richard M BergenstalRaffaella Balena
Mar 20, 2013·International Journal of Epidemiology·Areti Angeliki VeronikiGeorgia Salanti
Oct 8, 2013·PloS One·Anna ChaimaniGeorgia Salanti
Oct 15, 2013·Diabetic Medicine : a Journal of the British Diabetic Association·G B BolliM Hanefeld
Nov 8, 2013·Diabetes Care·Lydia W TurnerG Caleb Alexander
Apr 12, 2014·Diabetes Care·Hans-Ulrich HäringUNKNOWN EMPA-REG MET Trial Investigators

❮ Previous
Next ❯

Citations

Jul 3, 2021·Journal of Clinical Medicine·Vicente Martínez-VizcaínoIván Cavero-Redondo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.